These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

378 related articles for article (PubMed ID: 28771049)

  • 41. News at XI: moving beyond factor Xa inhibitors.
    Fredenburgh JC; Weitz JI
    J Thromb Haemost; 2023 Jul; 21(7):1692-1702. PubMed ID: 37116752
    [TBL] [Abstract][Full Text] [Related]  

  • 42. New oral anticoagulants for the treatment of venous thromboembolism.
    Agnelli G; Becattini C; Franco L
    Best Pract Res Clin Haematol; 2013 Jun; 26(2):151-61. PubMed ID: 23953903
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Evaluation of oral anticoagulants for the extended treatment of venous thromboembolism using a mixed-treatment comparison, meta-analytic approach.
    Rollins BM; Silva MA; Donovan JL; Kanaan AO
    Clin Ther; 2014 Oct; 36(10):1454-64.e3. PubMed ID: 25092394
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Rivaroxaban for the treatment of venous thromboembolism. A "real-life" perspective in 103 patients.
    Jara-Palomares L; Sanchez-Oro-Gomez R; Elias-Hernandez T; Morillo-Guerrero R; Ferrer-Galvan M; Asensio-Cruz MI; Barrot-Cortes E; Otero-Candelera R
    Thromb Res; 2014 Sep; 134(3):617-21. PubMed ID: 25034320
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Specific antidotes against direct oral anticoagulants: A comprehensive review of clinical trials data.
    Tummala R; Kavtaradze A; Gupta A; Ghosh RK
    Int J Cardiol; 2016 Jul; 214():292-8. PubMed ID: 27082776
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Management of cancer-associated venous thromboembolism - a case-based practical approach.
    Voigtlaender M; Langer F
    Vasa; 2018 Feb; 47(2):77-89. PubMed ID: 29325495
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Benefit-risk profile of non-vitamin K antagonist oral anticoagulants in the management of venous thromboembolism.
    Beyer-Westendorf J; Ageno W
    Thromb Haemost; 2015 Feb; 113(2):231-46. PubMed ID: 25319150
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Moving toward a more ideal anticoagulant: the oral direct thrombin and factor Xa inhibitors.
    King CS; Holley AB; Moores LK
    Chest; 2013 Apr; 143(4):1106-1116. PubMed ID: 23546483
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Direct factor Xa inhibitors (rivaroxaban and apixaban) versus enoxaparin for the prevention of venous thromboembolism after total knee replacement: A meta-analysis of 6 randomized clinical trials.
    Ma G; Zhang R; Wu X; Wang D; Ying K
    Thromb Res; 2015 May; 135(5):816-22. PubMed ID: 25728496
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Managing the perioperative patient on direct oral anticoagulants.
    Leitch J; van Vlymen J
    Can J Anaesth; 2017 Jun; 64(6):656-672. PubMed ID: 28429198
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Pulmonary embolism: current and new treatment options.
    Walter RJ; Moores LK; Jiménez D
    Curr Med Res Opin; 2014 Oct; 30(10):1975-89. PubMed ID: 24983743
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Treatment of proximal deep-vein thrombosis with the oral direct factor Xa inhibitor rivaroxaban (BAY 59-7939): the ODIXa-DVT (Oral Direct Factor Xa Inhibitor BAY 59-7939 in Patients With Acute Symptomatic Deep-Vein Thrombosis) study.
    Agnelli G; Gallus A; Goldhaber SZ; Haas S; Huisman MV; Hull RD; Kakkar AK; Misselwitz F; Schellong S;
    Circulation; 2007 Jul; 116(2):180-7. PubMed ID: 17576867
    [TBL] [Abstract][Full Text] [Related]  

  • 53. A cost-analysis model for anticoagulant treatment in the hospital setting.
    Mody SH; Huynh L; Zhuo DY; Tran KN; Lefebvre P; Bookhart B
    J Med Econ; 2014 Jul; 17(7):492-8. PubMed ID: 24773068
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Hospital length of stay in patients initiated on direct oral anticoagulants versus warfarin for venous thromboembolism: a real-world single-center study.
    Badreldin H
    J Thromb Thrombolysis; 2018 Jul; 46(1):16-21. PubMed ID: 29626281
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Practical Considerations for the Use of Direct Oral Anticoagulants in Patients With Atrial Fibrillation.
    Stacy Z; Richter S
    Clin Appl Thromb Hemost; 2017 Jan; 23(1):5-19. PubMed ID: 26988835
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Therapeutic management of acute pulmonary embolism.
    Tromeur C; Van Der Pol LM; Couturaud F; Klok FA; Huisman MV
    Expert Rev Respir Med; 2017 Aug; 11(8):641-648. PubMed ID: 28580827
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Comparing Direct Oral Anticoagulants and Warfarin for Atrial Fibrillation, Venous Thromboembolism, and Mechanical Heart Valves.
    Marcy TR; Truong T; Rai A
    Consult Pharm; 2015 Nov; 30(11):644-56. PubMed ID: 26629800
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Thromboprophylaxis with enoxaparin and direct oral anticoagulants in major orthopedic surgery and acutely ill medical patients: a meta-analysis.
    Cimminiello C; Prandoni P; Agnelli G; Di Minno G; Polo Friz H; Scaglione F; Boracchi P; Marano G; Harenberg J
    Intern Emerg Med; 2017 Dec; 12(8):1291-1305. PubMed ID: 28756546
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Initial and Long-Term Treatment of Pulmonary Embolism: Current Approach and Future Perspectives.
    Donadini MP; Ageno W
    Hamostaseologie; 2018 May; 38(2):75-86. PubMed ID: 29843172
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Review of Medical Therapies for the Management of Pulmonary Embolism.
    Panahi L; Udeani G; Horseman M; Weston J; Samuel N; Joseph M; Mora A; Bazan D
    Medicina (Kaunas); 2021 Jan; 57(2):. PubMed ID: 33530544
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.